Multiple indications with unmet medical need
“Our company goal is to create new products that reach their target in the brain and act as a protector against nerve cells injury. Currently, there are no approved drugs that can slow down or halt neurodegeneration. We believe that EmtinB has potential to bridge this gap and bring this breakthrough medicine to clinics, bringing new hope to patients and their families”
The pharmaceutical industry has recently witnessed another raft of failures in drugs that target amyloid plaques as treatments for Alzheimer’s disease. The latest class of anti-plaque drugs to fail in mid-to-late stage clinical development are BACE Inhibitors; drugs that seek to block BACE enzymes which are involved in the production of the plaque forming amyloid protein.
While there is an association with plaque accumulation within the brain and the onset of Alzheimer’s disease, all drugs to date that have tried to either prevent or clear plaques have not been able to demonstrate a significant benefit in patients in late-stage clinical trials. These results reiterate the need for research to investigate other potential treatment pathways for Alzheimer’s disease, as the vast majority of Alzheimer’s research has relied on amyloid plaques and tau tangles as targets.
Our Company believes that the turning point in Alzheimer’s pathology is when the brain accumulates enough plaques and tangles to prompt the microglia response.
Microglia under normal conditions represents brain’s housekeeping squad cleaning away damaged neurons and their components to keep brain healthy. However, under pathological conditions such as Alzheimer’s, it can overact to accumulation of protein plaques and launch an all-out inflammatory attack on both harmful and healthy cells. This type of microglia is now classified as disease associated microglia.
We believe, EmtinB’s ability to modulate microglia induced neuroinflammation in Azheimer’s Disease and ability to activate neuronal pro-survival pathways leading to axonal regeneration is a game changing approach towards Alzheimer’s Disease.
OPTIC NERVE CONDITIONS
Glaucoma is an eye condition that causes damage to the nerve that connects the eye to the brain (optic nerve). It is one of the leading causes of blindness globally, with at least 60 million sufferers worldwide and affects 300,000 Australians. Current treatment options can help, but glaucoma cannot be cured, and vision loss is irreversible.
Glaucoma is caused by changes to the flow of fluid (aqueous humor) within the eye. Under normal circumstances, fluid is continuously produced and flows out of the eye, maintaining a steady ocular pressure. Most cases of glaucoma are due to increased pressure within the eye (intraocular pressure) caused by problems with drainage of the fluid. Ultimately pressure-driven damage to astrocytes (neuron supporting cells) and degeneration of neural cells (neurons) is responsible for vision loss in glaucoma.
Current treatment options help reduce intraocular pressure and slow down further vision loss and disease progression. Unfortunately, correcting the eye pressure alone does not guarantee that there will be no further loss of vision. With current therapies, vision that has already been lost cannot be recovered.
We believe that EmtinB could become a potent agent able to protect the astrocytes and retinal ganglion cells of the optic nerve from damage associated with elevated intraocular pressure and therefore completely stop and potentially reverse progression of Glaucoma.
Continuously innovating with focus and integrity
A pipeline of potential therapeutic candidates with strong IP protection, backed up by an experienced board and management team, validated strategy and business model and strong strategic partnerships geared towards success.